PMID-31786365 – Antimicrobial Peptides as Therapeutics for NSCLC
Kunda NK. "Antimicrobial peptides as novel therapeutics for non-small cell lung cancer," Drug Discovery Today, 2020;25(1):238-247. doi:10.1016/j.drudis.2019.11.012
Quick Reference
| Property | Value |
|---|---|
| PMID | 31786365 |
| DOI | 10.1016/j.drudis.2019.11.012 |
| Year | 2020 |
| Journal | Drug Discovery Today |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | N/A (review) |
| Peptide(s) Studied | LL-37, defensins, magainin 2, cecropin, and other antimicrobial peptides |
Key Findings
- Antimicrobial peptides (AMPs) including LL-37 demonstrate selective cytotoxicity against non-small cell lung cancer (NSCLC) cells while sparing normal cells
- The selectivity arises from differences in membrane composition: cancer cells have higher negative surface charge (increased phosphatidylserine exposure) compared to normal cells
- LL-37 specifically induces cancer cell death through membrane disruption, mitochondrial depolarization, and apoptotic pathway activation
- AMPs show low propensity for drug resistance development compared to conventional chemotherapy, as they target fundamental membrane properties rather than specific molecular targets
- Combination strategies pairing AMPs with conventional chemotherapeutics show synergistic effects and may reduce chemotherapy dose requirements
- Pulmonary delivery of AMPs via inhalation is proposed as a route to achieve high local concentrations at tumor sites while minimizing systemic toxicity
Study Design
Narrative review examining the rationale, mechanisms, and preclinical evidence for using antimicrobial peptides as anticancer agents in NSCLC. Covers membrane-targeting mechanisms, selectivity determinants, and emerging delivery strategies.
Limitations
- Narrative review without systematic methodology
- Most evidence for AMPs in NSCLC is preclinical (in vitro and animal models)
- No human clinical trial data for AMP-based cancer therapy at the time of publication
- Pharmacokinetic challenges (short half-life, protease degradation) not fully addressed
- The dual role of LL-37 in cancer (pro-tumorigenic in some contexts) is acknowledged but not deeply explored
Clinical Relevance
This review provides mechanistic justification for investigating AMPs, particularly LL-37, as novel anticancer agents in NSCLC. The low resistance potential and selectivity for cancer cells are attractive features. However, the evidence remains preclinical, and the known dual role of LL-37 in cancer (see PMID-29843147) requires careful consideration. Practitioners should understand this evolving research area but recognize that therapeutic AMP use in oncology remains investigational.
Related
#research #narrative-review #evidence-level-V #cancer